?Global Drugs for Herpes Labialis research
?Global Drugs for Herpes Labialis research

Drugs for Herpes Labialis Comprehensive Study by Type (Aciclovir, Valacyclovir, Famciclovir, Docosanol, Other), Route of Administration (External Use, Oral, Injection), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Drugs for Herpes Labialis Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 250 Pages 165 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Drugs for Herpes Labialis Market Overview:
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2?3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.The global Drugs For Herpes Labialis (Oral Herpes) market will reach xxx Million USD in 2019 and CAGR xx% 2019-2024. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Drugs For Herpes Labialis (Oral Herpes) by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are Some of the players profiled in the study are GSK (United Kingdom), Novartis (Switzerland), Teva (Israel), Mylan (United States), Cadila (India), Apotex (Canada), Daewoong Pharmaceutical (South Korea), Glenmark Pharmaceuticals (India), Blistex (United States) and Hikma Pharmaceuticals (United Kingdom).

On the basis of geography, the market of Drugs for Herpes Labialis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. External Use will boost the Drugs for Herpes Labialis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Drugs for Herpes Labialis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing Problems Related to Herpes Labialis
  • Increase in Modes of Transmission of the Infectious Disease and Lack of Cleanliness

Influencing Trend
  • Low level laser therapy (LLLT) has been considered as a Possible Treatment for Herpes Labialis Restraints

Restraints
  • Several Times Home Remedies do the Trick
  • Only Handful of Drugs Available in the Market

Opportunities
  • Increasing Research and Development Activities

Challenges
  • Various Regulator Factors
  • Lack of Awareness About the Treatment




The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Target Audience:
Pharmaceutical Companies, Research Institutions, Healthcare Industry, Regulatory Bodies and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Drugs for Herpes Labialis market on the basis of product [Aciclovir, Valacyclovir, Famciclovir, Docosanol and Other] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Drugs for Herpes Labialis market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Drugs for Herpes Labialis industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Livzon (China) and Med shine (Philippines).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Drugs for Herpes Labialis market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • Aciclovir
  • Valacyclovir
  • Famciclovir
  • Docosanol
  • Other
By Route of Administration
  • External Use
  • Oral
  • Injection

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Problems Related to Herpes Labialis
      • 3.2.2. Increase in Modes of Transmission of the Infectious Disease and Lack of Cleanliness
    • 3.3. Market Challenges
      • 3.3.1. Various Regulator Factors
      • 3.3.2. Lack of Awareness About the Treatment
    • 3.4. Market Trends
      • 3.4.1. Low level laser therapy (LLLT) has been considered as a Possible Treatment for Herpes Labialis Restraints
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drugs for Herpes Labialis, by Type, Route of Administration, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Drugs for Herpes Labialis (Value)
      • 5.2.1. Global Drugs for Herpes Labialis by: Type (Value)
        • 5.2.1.1. Aciclovir
        • 5.2.1.2. Valacyclovir
        • 5.2.1.3. Famciclovir
        • 5.2.1.4. Docosanol
        • 5.2.1.5. Other
      • 5.2.2. Global Drugs for Herpes Labialis by: Route of Administration (Value)
        • 5.2.2.1. External Use
        • 5.2.2.2. Oral
        • 5.2.2.3. Injection
      • 5.2.3. Global Drugs for Herpes Labialis by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Drugs for Herpes Labialis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Drugs for Herpes Labialis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GSK (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cadila (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Apotex (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Daewoong Pharmaceutical (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Glenmark Pharmaceuticals (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Blistex (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hikma Pharmaceuticals (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drugs for Herpes Labialis Sale, by Type, Route of Administration, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Drugs for Herpes Labialis (Value)
      • 7.2.1. Global Drugs for Herpes Labialis by: Type (Value)
        • 7.2.1.1. Aciclovir
        • 7.2.1.2. Valacyclovir
        • 7.2.1.3. Famciclovir
        • 7.2.1.4. Docosanol
        • 7.2.1.5. Other
      • 7.2.2. Global Drugs for Herpes Labialis by: Route of Administration (Value)
        • 7.2.2.1. External Use
        • 7.2.2.2. Oral
        • 7.2.2.3. Injection
      • 7.2.3. Global Drugs for Herpes Labialis by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Drugs for Herpes Labialis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drugs for Herpes Labialis: by Type(USD Million)
  • Table 2. Drugs for Herpes Labialis Aciclovir , by Region USD Million (2015-2020)
  • Table 3. Drugs for Herpes Labialis Valacyclovir , by Region USD Million (2015-2020)
  • Table 4. Drugs for Herpes Labialis Famciclovir , by Region USD Million (2015-2020)
  • Table 5. Drugs for Herpes Labialis Docosanol , by Region USD Million (2015-2020)
  • Table 6. Drugs for Herpes Labialis Other , by Region USD Million (2015-2020)
  • Table 7. Drugs for Herpes Labialis: by Route of Administration(USD Million)
  • Table 8. Drugs for Herpes Labialis External Use , by Region USD Million (2015-2020)
  • Table 9. Drugs for Herpes Labialis Oral , by Region USD Million (2015-2020)
  • Table 10. Drugs for Herpes Labialis Injection , by Region USD Million (2015-2020)
  • Table 11. Drugs for Herpes Labialis: by Distribution Channel(USD Million)
  • Table 12. Drugs for Herpes Labialis Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Drugs for Herpes Labialis Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 14. Drugs for Herpes Labialis Online Pharmacies , by Region USD Million (2015-2020)
  • Table 15. South America Drugs for Herpes Labialis, by Country USD Million (2015-2020)
  • Table 16. South America Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 17. South America Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 18. South America Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 19. Brazil Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 20. Brazil Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 21. Brazil Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 22. Argentina Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 23. Argentina Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 24. Argentina Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 25. Rest of South America Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 26. Rest of South America Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 27. Rest of South America Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 28. Asia Pacific Drugs for Herpes Labialis, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 30. Asia Pacific Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 31. Asia Pacific Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 32. China Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 33. China Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 34. China Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 35. Japan Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 36. Japan Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 37. Japan Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 38. India Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 39. India Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 40. India Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 41. South Korea Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 42. South Korea Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 43. South Korea Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 44. Taiwan Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 45. Taiwan Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 46. Taiwan Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 47. Australia Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 48. Australia Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 49. Australia Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 53. Europe Drugs for Herpes Labialis, by Country USD Million (2015-2020)
  • Table 54. Europe Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 55. Europe Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 56. Europe Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 57. Germany Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 58. Germany Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 59. Germany Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 60. France Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 61. France Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 62. France Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 63. Italy Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 64. Italy Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 65. Italy Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 66. United Kingdom Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 67. United Kingdom Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 68. United Kingdom Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 69. Netherlands Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 70. Netherlands Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 71. Netherlands Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 72. Rest of Europe Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 73. Rest of Europe Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 74. Rest of Europe Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 75. MEA Drugs for Herpes Labialis, by Country USD Million (2015-2020)
  • Table 76. MEA Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 77. MEA Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 78. MEA Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 79. Middle East Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 80. Middle East Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 81. Middle East Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 82. Africa Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 83. Africa Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 84. Africa Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 85. North America Drugs for Herpes Labialis, by Country USD Million (2015-2020)
  • Table 86. North America Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 87. North America Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 88. North America Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 89. United States Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 90. United States Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 91. United States Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 92. Canada Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 93. Canada Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 94. Canada Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 95. Mexico Drugs for Herpes Labialis, by Type USD Million (2015-2020)
  • Table 96. Mexico Drugs for Herpes Labialis, by Route of Administration USD Million (2015-2020)
  • Table 97. Mexico Drugs for Herpes Labialis, by Distribution Channel USD Million (2015-2020)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Drugs for Herpes Labialis: by Type(USD Million)
  • Table 109. Drugs for Herpes Labialis Aciclovir , by Region USD Million (2021-2026)
  • Table 110. Drugs for Herpes Labialis Valacyclovir , by Region USD Million (2021-2026)
  • Table 111. Drugs for Herpes Labialis Famciclovir , by Region USD Million (2021-2026)
  • Table 112. Drugs for Herpes Labialis Docosanol , by Region USD Million (2021-2026)
  • Table 113. Drugs for Herpes Labialis Other , by Region USD Million (2021-2026)
  • Table 114. Drugs for Herpes Labialis: by Route of Administration(USD Million)
  • Table 115. Drugs for Herpes Labialis External Use , by Region USD Million (2021-2026)
  • Table 116. Drugs for Herpes Labialis Oral , by Region USD Million (2021-2026)
  • Table 117. Drugs for Herpes Labialis Injection , by Region USD Million (2021-2026)
  • Table 118. Drugs for Herpes Labialis: by Distribution Channel(USD Million)
  • Table 119. Drugs for Herpes Labialis Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 120. Drugs for Herpes Labialis Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 121. Drugs for Herpes Labialis Online Pharmacies , by Region USD Million (2021-2026)
  • Table 122. South America Drugs for Herpes Labialis, by Country USD Million (2021-2026)
  • Table 123. South America Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 124. South America Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 125. South America Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 126. Brazil Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 127. Brazil Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 128. Brazil Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 129. Argentina Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 130. Argentina Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 131. Argentina Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 132. Rest of South America Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 133. Rest of South America Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 134. Rest of South America Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 135. Asia Pacific Drugs for Herpes Labialis, by Country USD Million (2021-2026)
  • Table 136. Asia Pacific Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 137. Asia Pacific Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 138. Asia Pacific Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 139. China Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 140. China Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 141. China Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 142. Japan Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 143. Japan Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 144. Japan Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 145. India Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 146. India Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 147. India Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 148. South Korea Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 149. South Korea Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 150. South Korea Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 151. Taiwan Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 152. Taiwan Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 153. Taiwan Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 154. Australia Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 155. Australia Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 156. Australia Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 160. Europe Drugs for Herpes Labialis, by Country USD Million (2021-2026)
  • Table 161. Europe Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 162. Europe Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 163. Europe Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 164. Germany Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 165. Germany Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 166. Germany Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 167. France Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 168. France Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 169. France Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 170. Italy Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 171. Italy Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 172. Italy Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 173. United Kingdom Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 174. United Kingdom Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 175. United Kingdom Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 176. Netherlands Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 177. Netherlands Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 178. Netherlands Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 179. Rest of Europe Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 180. Rest of Europe Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 181. Rest of Europe Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 182. MEA Drugs for Herpes Labialis, by Country USD Million (2021-2026)
  • Table 183. MEA Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 184. MEA Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 185. MEA Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 186. Middle East Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 187. Middle East Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 188. Middle East Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 189. Africa Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 190. Africa Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 191. Africa Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 192. North America Drugs for Herpes Labialis, by Country USD Million (2021-2026)
  • Table 193. North America Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 194. North America Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 195. North America Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 196. United States Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 197. United States Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 198. United States Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 199. Canada Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 200. Canada Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 201. Canada Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 202. Mexico Drugs for Herpes Labialis, by Type USD Million (2021-2026)
  • Table 203. Mexico Drugs for Herpes Labialis, by Route of Administration USD Million (2021-2026)
  • Table 204. Mexico Drugs for Herpes Labialis, by Distribution Channel USD Million (2021-2026)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drugs for Herpes Labialis: by Type USD Million (2015-2020)
  • Figure 5. Global Drugs for Herpes Labialis: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Drugs for Herpes Labialis: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Drugs for Herpes Labialis Share (%), by Country
  • Figure 8. Asia Pacific Drugs for Herpes Labialis Share (%), by Country
  • Figure 9. Europe Drugs for Herpes Labialis Share (%), by Country
  • Figure 10. MEA Drugs for Herpes Labialis Share (%), by Country
  • Figure 11. North America Drugs for Herpes Labialis Share (%), by Country
  • Figure 12. Global Drugs for Herpes Labialis share by Players 2020 (%)
  • Figure 13. Global Drugs for Herpes Labialis share by Players (Top 3) 2020(%)
  • Figure 14. Global Drugs for Herpes Labialis share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 18. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 20. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 21. Teva (Israel) Revenue: by Geography 2020
  • Figure 22. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 23. Mylan (United States) Revenue: by Geography 2020
  • Figure 24. Cadila (India) Revenue, Net Income and Gross profit
  • Figure 25. Cadila (India) Revenue: by Geography 2020
  • Figure 26. Apotex (Canada) Revenue, Net Income and Gross profit
  • Figure 27. Apotex (Canada) Revenue: by Geography 2020
  • Figure 28. Daewoong Pharmaceutical (South Korea) Revenue, Net Income and Gross profit
  • Figure 29. Daewoong Pharmaceutical (South Korea) Revenue: by Geography 2020
  • Figure 30. Glenmark Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 31. Glenmark Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 32. Blistex (United States) Revenue, Net Income and Gross profit
  • Figure 33. Blistex (United States) Revenue: by Geography 2020
  • Figure 34. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2020
  • Figure 36. Global Drugs for Herpes Labialis: by Type USD Million (2021-2026)
  • Figure 37. Global Drugs for Herpes Labialis: by Route of Administration USD Million (2021-2026)
  • Figure 38. Global Drugs for Herpes Labialis: by Distribution Channel USD Million (2021-2026)
  • Figure 39. South America Drugs for Herpes Labialis Share (%), by Country
  • Figure 40. Asia Pacific Drugs for Herpes Labialis Share (%), by Country
  • Figure 41. Europe Drugs for Herpes Labialis Share (%), by Country
  • Figure 42. MEA Drugs for Herpes Labialis Share (%), by Country
  • Figure 43. North America Drugs for Herpes Labialis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GSK (United Kingdom)
  • Novartis (Switzerland)
  • Teva (Israel)
  • Mylan (United States)
  • Cadila (India)
  • Apotex (Canada)
  • Daewoong Pharmaceutical (South Korea)
  • Glenmark Pharmaceuticals (India)
  • Blistex (United States)
  • Hikma Pharmaceuticals (United Kingdom)
Additional players considered in the study are as follows:
Livzon (China) , Med shine (Philippines)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation